Replies to post #125972 on Innovation Pharmaceuticals Inc (IPIX)

[rule_rationale]

Since the only "up to 6 months" timeframe in the primary outcome measures is Maximum Tolerated Dose (MTD) and we're already finishing the final Max Administered Dose (MAD) cohorts, I figure the "up to 4 weeks" timeframe of Dose Limiting Toxicity (DLT) is the only active primary at this point. I kind of expect our CEO to announce that "Kevetrin has successfully met all primary endpoints in the Phase I study at Dana Farber" by end of 2015. Then, up to 6 months later the study will have data on all secondary endpoints.